An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection
비강내 OMV 기반 백신은 SARS-CoV-2 감염에 대한 높은 점막 및 전신 보호 면역을 유도합니다
Immunology
[키워드] administer
Administered
administration
Against
antibody
booster vaccination
booster vaccinations
candidate vaccine
CHO cells
clinical development
clinical testing
control group
control groups
COVID-19
COVID-19 vaccine
COVID-19 vaccines
Cramp
D614G
effective
eight
greater
hamster
hamsters
Histopathology
IgA
IgG
IgG response
immune protection
immune response
Immunity
Immunoglobulin
Immunoglobulin G
inactivated
induce
intramuscular
intramuscular vaccination
intramuscularly
intranasal
intranasally
lesion
Local
lung
Lungs
majority
membrane vesicles
mice
mRNA
mucosal
mucosal immunity
Neisseria
Neisseria meningitidis
Neutralizing antibodies
nose
offer
OMV
outer membrane
outer membrane vesicle
pandemic
peptide
peptide sequence
practicality
produced
proline
Protecting
reduced
Registered
required
SARS-CoV-2
SARS-CoV-2 pandemic
second vaccination
sequence
serum
Spike protein
subunit
Subunit vaccine
Support
systemic
the SARS-CoV-2
Transmission
vaccination
Vaccinations
Vaccine
variants
Vesicle
Viral
viral entry
viral replication
Viral vector
weight loss
[DOI] 10.3389/fimmu.2021.781280 PMC 바로가기 [Article Type] Immunology
[DOI] 10.3389/fimmu.2021.781280 PMC 바로가기 [Article Type] Immunology